Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel Free ALLO Stock Alerts

Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume

Allogene Therapeutics logo
$2.04 -0.13 (-5.99%)
As of 04:00 PM Eastern
Compare

Allogene Therapeutics Short Interest Overview

As of August 14, 2026, Allogene Therapeutics (ALLO) had a short interest of 58.95 million shares sold short, representing 19.66% of the public float. This marks a -2.98% decrease in short interest since the prior report. The short interest ratio (days to cover) is 11.9, meaning it would take 11.9 days of the average trading volume of 8.06 million shares to cover all short positions.

Current Short Interest
58,945,687 shares
Previous Short Interest
60,753,788 shares
Change Vs. Previous Month
-2.98%
Dollar Volume Sold Short
$120.84 million
Short Interest Ratio
11.9 Days to Cover
Last Record Date
August 14, 2026
Outstanding Shares
345,490,000 shares
Short Percent of Float
19.66%
Today's Trading Volume
4,996,405 shares
Average Trading Volume
8,062,687 shares
Today's Volume Vs. Average
62%
Short Selling Allogene Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Allogene Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

ALLO Short Interest Over Time

ALLO Days to Cover Over Time

ALLO Percentage of Float Shorted Over Time

Allogene Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/14/202658,945,687 shares $120.84 million -3.0%19.7%11.93 $2.05
7/31/202660,753,788 shares $114.22 million +1.7%20.3%9.23 $1.88
7/15/202659,712,398 shares $113.45 million -5.8%19.9%6.35 $1.90
6/30/202663,385,047 shares $131.84 million +32.0%21.2%5.14 $2.08
6/15/202648,035,062 shares $93.19 million +8.0%16.0%6.21 $1.94
5/29/202644,480,150 shares $96.52 million +5.2%14.8%6.77 $2.17
5/15/202642,275,161 shares $84.55 million +14.7%14.1%6.41 $2.00
4/30/202636,856,587 shares $78.50 million +1.3%17.3%3.71 $2.13
4/15/202636,379,520 shares $78.94 million +13.5%12.1%1.6 $2.17
3/31/202632,060,091 shares $78.23 million +31.3%10.7%4.81 $2.44
3/13/202624,421,757 shares $58.61 million +2.1%11.5%6.21 $2.40
2/27/202623,927,216 shares $66.52 million +19.9%8.0%3.96 $2.78
2/13/202619,964,416 shares $35.94 million +6.1%6.7%3.74 $1.80
1/30/202618,819,473 shares $34.63 million +1.0%9.6%2.59 $1.84
1/15/202618,633,438 shares $30.00 million +3.1%9.6%3.51 $1.61
12/31/202518,077,704 shares $24.77 million +0.2%9.3%6.36 $1.37
12/15/202518,038,394 shares $26.52 million -3.4%9.2%7.53 $1.47
11/28/202518,663,734 shares $27.44 million -0.2%9.6%7.62 $1.47
11/14/202518,695,485 shares $23.00 million -2.1%9.6%8.02 $1.23
10/31/202519,094,028 shares $23.68 million -2.0%9.8%7.68 $1.24
10/15/202519,490,000 shares $24.75 million +1.5%10.1%5 $1.27
9/30/202519,200,000 shares $23.81 million -5.4%N/A4.9 $1.24
9/15/202520,290,000 shares $23.33 million +1.8%N/A5 $1.15
8/31/202519,940,000 shares $22.53 million -18.5%10.4%5.1 $1.13
8/15/202524,470,000 shares $26.92 million +0.1%N/A6.3 $1.10
7/31/202524,450,000 shares $30.07 million -5.7%12.9%6.2 $1.23
7/15/202525,930,000 shares $32.15 million -2.4%N/A7.8 $1.24
6/30/202526,570,000 shares $30.02 million +2.0%14.0%8.1 $1.13
6/15/202526,040,000 shares $34.89 million +6.0%13.7%8.6 $1.34
5/31/202524,570,000 shares $28.62 million -10.2%15.5%7.4 $1.17
5/15/202527,360,000 shares $29.82 million -9.2%17.2%7.9 $1.09
4/30/202530,130,000 shares $50.62 million -8.2%N/A5.5 $1.68
4/15/202532,810,000 shares $47.90 million -5.6%20.7%6.3 $1.46
3/31/202534,760,000 shares $50.75 million -8.6%24.9%6.5 $1.46
3/15/202538,010,000 shares $73.74 million -2.8%27.2%7.1 $1.94
2/28/202539,100,000 shares $76.25 million +16.2%29.1%7.6 $1.95
2/15/202533,660,000 shares $68.67 million +5.0%25.0%6.7 $2.04
1/31/202532,050,000 shares $57.69 million -0.9%22.8%11.7 $1.80
1/15/202532,350,000 shares $60.49 million +4.7%N/A12 $1.87
12/31/202430,910,000 shares $65.84 million -4.5%N/A12.4 $2.13
The retirement stock I'd buy before Nvidia today (Ad)

In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel

Get Marc Chaikin's free presentation on this overlooked AI stock now
12/15/202432,370,000 shares $61.18 million +3.9%N/A14.1 $1.89
11/30/202431,170,000 shares $77.30 million -11.1%N/A13.8 $2.48
11/15/202435,050,000 shares $79.56 million -5.4%N/A16.2 $2.27
10/31/202437,040,000 shares $94.64 million -5.8%26.7%18.7 $2.56
10/15/202439,320,000 shares $106.56 million +2.1%28.5%21.7 $2.71
9/30/202438,510,000 shares $107.83 million -1.7%28.2%18.3 $2.80
9/15/202439,190,000 shares $116.00 million +0.6%28.7%17 $2.96
8/31/202438,940,000 shares $102.41 million -0.7%28.5%15.8 $2.63
8/15/202439,230,000 shares $90.23 million +3.9%28.7%14.5 $2.30
7/31/202437,750,000 shares $110.99 million -12.7%27.6%12.9 $2.94
7/15/202443,230,000 shares $128.83 million +4.5%31.6%14.7 $2.98
6/30/202441,380,000 shares $96.42 million -4.4%30.3%15.3 $2.33
6/15/202443,280,000 shares $101.71 million +6.7%31.7%17.1 $2.35
5/31/202440,570,000 shares $101.43 million +11.4%33.5%16.2 $2.50
5/15/202436,430,000 shares $108.56 million +7.6%30.1%15.7 $2.98
4/30/202433,870,000 shares $93.48 million +8.0%32.0%15.5 $2.76
4/15/202431,360,000 shares $111.33 million +2.4%30.0%13.9 $3.55
3/31/202430,620,000 shares $136.87 million +10.3%29.3%11.7 $4.47
3/15/202427,750,000 shares $129.32 million +11.0%26.6%10 $4.66
2/29/202425,010,000 shares $122.80 million +6.7%24.1%8.3 $4.91
2/15/202423,450,000 shares $116.31 million +1.6%22.6%7.7 $4.96
1/31/202423,090,000 shares $81.28 million -23.6%22.2%7.4 $3.52
1/15/202430,210,000 shares $97.28 million -3.5%28.5%10.3 $3.22
12/31/202331,320,000 shares $100.54 million -6.7%29.6%11.9 $3.21
12/15/202333,550,000 shares $90.92 million +5.3%31.7%14.3 $2.71
11/30/202331,860,000 shares $74.87 million -1.5%30.1%16.8 $2.35
11/15/202332,340,000 shares $87.96 million -5.0%30.6%18.9 $2.72
10/31/202334,030,000 shares $95.96 million +10.7%32.2%22 $2.82
10/15/202330,730,000 shares $98.03 million -10.0%29.2%18 $3.19
9/30/202334,130,000 shares $108.19 million +2.1%32.2%19 $3.17
9/15/202333,420,000 shares $130.00 million +4.1%31.5%16.2 $3.89
8/31/202332,110,000 shares $124.91 million -2.0%30.3%12.4 $3.89
8/15/202332,770,000 shares $133.70 million -13.6%30.9%12.5 $4.08
7/31/202337,910,000 shares $188.03 million -8.1%39.4%14.3 $4.96
7/15/202341,260,000 shares $204.65 million +8.1%53.9%15.3 $4.96
6/30/202338,180,000 shares $189.75 million +1.7%49.9%14.1 $4.97
6/15/202337,560,000 shares $186.67 million -6.2%49.1%15.1 $4.97
5/31/202340,030,000 shares $210.16 million -1.4%52.1%20.4 $5.25
5/15/202340,590,000 shares $273.58 million -0.2%52.8%19.6 $6.74
4/30/202340,650,000 shares $220.73 million -1.4%53.3%20.3 $5.43
4/15/202341,220,000 shares $205.69 million +0.5%54.5%22.2 $4.99
3/31/202341,010,000 shares $202.59 million +3.0%54.3%22.5 $4.94
3/15/202339,800,000 shares $225.27 million +8.0%49.6%20.9 $5.66
2/28/202336,860,000 shares $234.06 million +4.9%46.0%19.4 $6.35
2/15/202335,140,000 shares $254.06 million +2.1%44.0%18.4 $7.23
1/31/202334,410,000 shares $265.65 million +0.7%43.1%18 $7.72
1/15/202334,160,000 shares $241.17 million +2.2%42.7%18.1 $7.06
12/30/202233,430,000 shares $210.27 million +9.5%41.8%18 $6.29
12/15/202230,530,000 shares $216.15 million +0.2%38.2%16 $7.08
11/30/202230,470,000 shares $300.43 million -3.2%38.1%16.5 $9.86
Buffett's Final Warning: "The Dollar Is Going to Hell" (Ad)

On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel

Watch how to protect yourself from what Dalio and Buffett see coming (free training).
11/15/202231,460,000 shares $311.45 million +1.6%39.3%18.2 $9.90
10/31/202230,960,000 shares $318.89 million +3.0%39.3%18.3 $10.30
10/15/202230,050,000 shares $305.91 million +8.9%38.3%18 $10.18
9/30/202227,590,000 shares $297.97 million +24.2%35.2%16 $10.80
9/15/202222,220,000 shares $311.08 million +0.9%28.3%12.8 $14.00
8/31/202222,020,000 shares $301.89 million -2.4%28.1%12 $13.71
8/15/202222,570,000 shares $390.01 million +0.8%28.8%11.6 $17.28
7/31/202222,400,000 shares $290.75 million -0.1%28.6%10.9 $12.98
7/15/202222,430,000 shares $287.33 million -0.3%28.6%10.2 $12.81
6/30/202222,490,000 shares $256.39 million +2.0%28.5%10.5 $11.40
6/15/202222,060,000 shares $212.22 million +9.5%28.0%10.8 $9.62
5/31/202220,150,000 shares $159.79 million +13.9%25.7%10.8 $7.93
5/15/202217,690,000 shares $127.90 million -0.4%22.5%9.6 $7.23
4/30/202217,760,000 shares $148.30 million -1.7%24.3%10.4 $8.35
4/15/202218,060,000 shares $149.00 million +18.6%24.8%11.4 $8.25
3/31/202215,230,000 shares $138.75 million +4.8%16.1%8.9 $9.11
3/15/202214,540,000 shares $113.41 million +18.7%19.8%8.6 $7.80
2/28/202212,250,000 shares $112.09 million +16.9%16.7%7.5 $9.15
2/15/202210,480,000 shares $106.79 million +10.0%14.3%6.8 $10.19
1/31/20229,530,000 shares $109.12 million +5.1%14.3%6.6 $11.45
1/15/20229,070,000 shares $120.45 million +19.7%13.6%6.2 $13.28
12/31/20217,580,000 shares $113.09 million +34.9%11.4%4.1 $14.92
12/15/20215,620,000 shares $86.38 million +4.7%8.4%2.7 $15.37
11/30/20215,370,000 shares $99.29 million -5.3%8.1%2.9 $18.49
11/15/20215,670,000 shares $106.99 million +19.6%8.5%3.1 $18.87
10/29/20214,740,000 shares $81.72 million +0.2%7.1%2.6 $17.24
10/15/20214,730,000 shares $77.95 million -40.7%7.1%2.8 $16.48
9/30/20217,980,000 shares $205.09 million +1.7%12.0%6.7 $25.70
9/15/20217,850,000 shares $196.25 million -6.0%11.8%9.5 $25.00
8/31/20218,350,000 shares $199.15 million -0.4%11.7%9.4 $23.85

ALLO Short Interest - Frequently Asked Questions

Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 14th, investors have sold 58,945,687 shares of ALLO short. 19.66% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 11.9. Learn More on Allogene Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.66% of Allogene Therapeutics' floating shares are currently sold short.

Allogene Therapeutics saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 58,945,687 shares, a decline of 3.0% from the previous total of 60,753,788 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

19.66% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Allogene Therapeutics: Nurix Therapeutics, Inc. (18.57%), Beam Therapeutics Inc. (24.53%), Ultragenyx Pharmaceutical Inc. (17.00%), SELLAS Life Sciences Group, Inc. (28.28%), Hemab Therapeutics Holdings, Inc. (4.35%), Kodiak Sciences Inc. (29.49%), Viridian Therapeutics, Inc. (17.21%), BioCryst Pharmaceuticals, Inc. (13.40%), Nektar Therapeutics (18.53%), Amylyx Pharmaceuticals, Inc. (13.52%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.57 billion), Invesco QQQ ($46.97 billion), iShares Russell 2000 ETF ($24.02 billion), Nebius Group N.V. ($15.37 billion), Sandisk Corporation ($12.60 billion), SPDR S&P Biotech ETF ($12.14 billion), Western Digital Corporation ($10.32 billion), iShares 20+ Year Treasury Bond ETF ($8.38 billion), VanEck Semiconductor ETF ($7.62 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.07 billion). View all of the most shorted stocks.

Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is August, 14 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ALLO:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:ALLO is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/25/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
The New Kings of Cantillon
In 1720, Richard Cantillon discovered that new money never spreads evenly through an economy. It reaches certa...
Porter & Company | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Trump Unleashes "Banned" American Fuel
A newly reopened American mine holds a fuel source so potent that one pound can generate as much energy as 16,...
Monument Traders Alliance | Sponsoredtc pixel
Look at this $5 stock’s address
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...
Freedom Financial | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel